[18F]FDG PET/CT影像组学与人工智能在肺癌临床决策中的影响:其当前角色
本文综述[18F]FDG PET/CT影像组学及人工智能在肺癌(尤其非小细胞肺癌)管理中的作用,涵盖诊断、分期、肿瘤亚型识别和分子标志物检测,并讨论影像协议标准化、特征可重复性及需要广泛前瞻性研究等临床整合挑战。
要点
- [18F]FDG PET/CT影像组学结合人工智能可提升肺癌诊断、分期、亚型识别和分子标志物检测能力。
- 影像协议标准化、特征可重复性和需要广泛前瞻性研究是临床整合的主要挑战。
- 影像组学与人工智能有望实现更个性化和有效的肺癌治疗。
核心结论
- 影像组学与人工智能有望实现更个性化和有效的肺癌治疗,可能改变疾病管理。
研究设计与样本
- 综述,探讨[18F]FDG PET/CT影像组学尤其结合人工智能在肺癌管理中的作用。
主要发现
- 传统PET/CT依赖定性分析和基本定量参数,影像组学提供更先进的肿瘤表型分析方法。
- 影像组学与人工智能可改善诊断、分期、肿瘤亚型识别和分子标志物检测,从而影响治疗决策。
局限性
- 临床整合面临影像协议标准化和特征可重复性的挑战。
- 需要广泛的前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer remains one of the most prevalent cancers globally and the leading cause of cancer-related deaths, accounting for nearly one-fifth of all cancer fatalities. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) plays a vital role in assessing lung cancer and managing disease progression. While traditional PET/CT imaging relies on qualitative analysis and basic quantitative parameters, radiomics offers a more advanced approach to analyzing tumor phenotypes. Recently, radiomics has gained attention for its potential to enhance the prognostic and diagnostic capabilities of [18F]FDG PET/CT in various cancers. This review explores the expanding role of [18F]FDG PET/CT-based radiomics, particularly when integrated with artificial intelligence (AI), in managing lung cancer, especially non-small cell lung cancer (NSCLC). We review how radiomics and AI improve diagnostics, staging, tumor subtype identification, and molecular marker detection, which influence treatment decisions. Additionally, we address challenges in clinical integration, such as imaging protocol standardization, feature reproducibility, and the need for extensive prospective studies. Ultimately, radiomics and AI hold great promise for enabling more personalized and effective lung cancer treatments, potentially transforming disease management.
引用
- Safarian A, Mirshahvalad SA, Nasrollahi H, et al. Impact of [18F]FDG PET/CT Radiomics and Artificial Intelligence in Clinical Decision Making in Lung Cancer: Its Current Role. Semin Nucl Med. 2025. PMID: 40050131. doi:10.1053/j.semnuclmed.2025.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。